Genomic Valley Biotech Limited

Healthcare — Biotechnology · BSE

₹34.30₹0.00 (0.00%)

DalalBaazaar Score

37 / 100

🔴 Weak

Verdict

CAUTION

Risk

High

Driven by negative free cash flow, micro-cap size, which brings thin liquidity, a very high earnings multiple, which leaves little margin for disappointment.

In simple words: The business is earning a fairly low return on the money invested in it, but sales are shrinking. Cash generation is currently the main factor to watch.

Decision support, not a buy or sell call.

As of 18 Oct 2026, 8:27 pm

Understanding the Business

Company site ↗

The 60-second version of Genomic Valley Biotech Limited — what it does, how it earns, and who it competes with, before any of the numbers below.

What does this company do?

Genomic Valley Biotech Limited operates in horticulture business activities in India.

IndustryBiotechnology

SectorHealthcare

Annual revenue₹0 Cr

How does it make money?

Turns over ₹0 Cr a year. Of every ₹100 of sales, about ₹11 reaches shareholders as profit, with ₹16 left at the operating level before interest, tax and depreciation.

Who are its competitors?

The closest listed comparisons in its industry are TATA CONSULTANCY SERV LT, INFOSYS LIMITED, HCL TECHNOLOGIES LTD, WIPRO LTD. These are the companies its valuation and returns are measured against elsewhere in this report.

Compared side by side in Peers ↓

What is its competitive advantage?Little sign of one

Returns on capital of 1.0% are at or below what the capital likely costs. That is the financial pattern of a business competing largely on price, where advantage has to come from execution rather than position.

Peer median ROE32.0%

What has been driving growth?

Growth has come mainly from selling more, rather than from keeping more of each sale. Over 3 years revenue moved -90% while net margin moved -52% relative to itself. What this cannot tell you is which products, customers or geographies did the work — that lives in the segment disclosures of the annual report.

Revenue effect-90%

Margin effect-52%

DalalBaazaar Score

37/ 100

Weak

Weighted across six categories. Every point is explained below.

✗ Revenue has contracted at 53.9% a year
✗ Profit has declined at 64.0% a year
✗ Profit fell 37.5% in the latest year

Quality vs. Valuation

Company Quality

37/ 100

Weak

How good the business is, ignoring the share price entirely.

Valuation

26/ 100

Expensive

What you are being asked to pay, ignoring how good the business is.

Weak on business quality and not cheap enough to compensate.

Historical Valuation

Current P/E

571.7x

3Y Median

26.2x

40 monthly readings · mean 445.5x · range 10.7x–2062.0x

Sector Median

16.5x

median of 4 sector peers

⚠️Current valuation is approximately 2082% above its 3y median of 26.2x. Paying more than usual needs a reason — faster growth, a better balance sheet, or a re-rating you believe in.

⚠️Against its sector it trades 3354% above the peer median of 16.5x.

vs. its own history

Expensive

26.2x median over 40 months · +2082%

vs. sector peers

Expensive

16.5x median of 4 peers · +3354%

vs. generic bands

Expensive

Above 35x

EV/EBITDA

239.4x

PEG

—

What's Good / What's Bad

🟢 What's Going Well1

Consistently profitable
Profitable in every one of the last 4 reported years.

🔴 What Needs Attention2

Return on equity is falling
ROE has dropped from 18.4% to 0.8% — each rupee of shareholder capital earns less than it did.
Return on capital is falling
ROCE has declined from 18.4% to 1.0% — often a sign of competition or overexpansion.

Red Flags

3 items require attention · 1 high · 2 watch

🔴Significant margin compressionFinancial
EBITDA margin has fallen 17.5 points, from 33.8% to 16.4%.
🟡Free cash flow is negativeFinancial
Free cash flow was -₹0 Cr in the latest year.
🟡Profit is decliningFinancial
Net profit is down 95% over 3 years.

Investment Thesis

🟢 Bull CaseWhat could make this work?

Earnings have proved durable
Profitable in every one of the last 4 reported years. Consistency lowers the risk that any single bad year is structural rather than cyclical.

🔴 Bear CaseWhat could go wrong?

Margins are being competed away
EBITDA margin has fallen from 33.8% to 16.4%. If the trend continues, profit falls even on flat sales — and margin decline rarely reverses quickly.
The price already assumes success
The stock trades 2082% above its own median multiple. At this level the business has to deliver just to stand still, and a stumble is repriced twice — lower earnings on a lower multiple.
Returns on shareholder capital are falling
ROE has dropped from 18.4% to 0.8%. Each rupee of equity earns less than it did, so profit growth increasingly depends on raising more capital rather than on the existing base working harder.
Earnings are hard to forecast
Profit has swung sharply from year to year, so any single year — good or bad — is a weak guide to the next. Cyclical earnings deserve lower multiples for that reason.
Size brings its own risk
Micro Cap businesses are thinly traded, so exits are harder in a falling market and single events move the price more than they would for a larger company.

🟡 Key Things to WatchMeasurable tripwires, set against where this company stands today

1EBITDA margin holds above 14%✓ 16.4%
Two points below today's level — enough room for noise, tight enough to catch real compression.
2Free cash flow remains positive✗ -₹0 Cr
Profit that never becomes cash eventually stops being profit.
3ROCE stays above 8%✗ 1.0%
Falling returns on capital are usually competition arriving, and show up here before they reach the margin.
4Valuation vs its own median of 26.2x✗ 571.7x today
A re-rating above its own history needs a reason; without one it is just a higher price.

Investment Checklist

3 / 10 checks passed

✗ Strong return on equity (ROE ≥ 15%)
✗ Strong return on capital employed (ROCE ≥ 15%)
✗ Healthy net margin (≥ 10%)
✗ Generates positive free cash flow
✓ Adequate short-term liquidity (Current Ratio ≥ 1.0)
✗ Revenue growing year-over-year
✗ Profit growing year-over-year
✗ Not trading at an extreme valuation (P/E < 40x)
✓ Not buying right at the 52-week high
✓ Short-term technical trend isn't bearish

Price history

Quick Metrics

1 good · 4 neutral · 6 weak

Market Cap

₹10 Cr

Micro Cap

Smaller company — thin liquidity and deep drawdowns are normal here

P/E (Trailing)

571.7x

Expensive

Expensive — verify against sector peers

P/B Ratio

2.66x

Fair

Moderate premium to the company's book value

EPS (TTM)

₹0.06

Profitable

Profitable on a per-share basis

ROE

0.8%

Weak

Weak capital efficiency

ROCE

1.0%

Weak

Low return on total capital employed

Debt/Equity

Not available

No data

Source didn't return this field

Revenue Growth (YoY)

-57.8%

Shrinking

Sales are contracting

Profit Growth (YoY)

-37.5%

Falling

Profits are shrinking

Dividend Yield

None

No dividend yield reported — usually means no payout, but verify if one was recently initiated

Free Cash Flow

-₹0 Cr

Cash burning

Spending more cash than the operations bring in

More Metrics

Operating Margin

38.5%

Good

Healthy core-business profitability

Net Margin

9.4%

Average

Average bottom-line conversion

Current Ratio

8.41

Comfortable

Healthy short-term liquidity

Beta (vs Nifty)

-0.16

Defensive

Steadier than the market

52W Range Position

78%

Mid-range

Technical Snapshot

SMA 20 / SMA 50

30.9 / 30.3

Bullish alignment (short > long)

Price vs SMA 200

Above

Long-term uptrend

RSI (14)

74.0

Overbought zone

Financial Trend (4-Year)

Metric	FY23	FY24	FY25	FY26	3Y CAGR
Revenue	₹3 Cr	₹0 Cr	₹1 Cr	₹0 Cr	-53.9%
EBITDA	₹1 Cr	₹0 Cr	₹0 Cr	₹0 Cr	-63.8%
EBITDA Margin	33.8%	10.6%	52.6%	16.4%	—
PAT (Net Profit)	₹1 Cr	₹0 Cr	₹0 Cr	₹0 Cr	-64.0%
EPS	₹2.12	₹0.05	₹1.17	₹0.1	-63.9%
ROE	18.4%	0.4%	9.1%	0.8%	—
ROCE	18.4%	0.4%	11.3%	1.0%	—
Free Cash Flow	-₹1 Cr	-₹0 Cr	₹0 Cr	-₹0 Cr	—

🔴 Revenue has shrunk at 53.9% a year over 3 years.

🔴 EBITDA has shrunk at 63.8% a year over 3 years.

🔴 EBITDA Margin has fallen from 33.8% to 16.4% over 3 years (-17.5 pts).

🔴 PAT (Net Profit) has shrunk at 64.0% a year over 3 years.

🔴 EPS has shrunk at 63.9% a year over 3 years.

🔴 ROE has fallen from 18.4% to 0.8% over 3 years (-17.6 pts).

🔴 ROCE has fallen from 18.4% to 1.0% over 3 years (-17.4 pts).

Balance Sheet & Cash Flow — FY2026

Total Assets

₹4 Cr

Total Liabilities

₹0 Cr

Total Debt

—

Cash & Equivalents

₹0 Cr

Operating Cash Flow

-₹0 Cr

Capex

—

Shareholding (proxy)

Institutional Holding

0.0%

Insider Holding

72.8%

Peer Comparison

Company	P/E	ROE
TATA CONSULTANCY SERV LT	17.3x	45.6%
INFOSYS LIMITED	15.8x	32.0%
HCL TECHNOLOGIES LTD	20.4x	24.6%
WIPRO LTD	14.5x	15.9%

Recent News

1 mixed5 general

Genomic Valley Biotech Ltd. Financials – Balance Sheet, Profit & Loss, Cash Flow

Value Research, 30 Aug

FARM PEACE LTD. Stock/Share price , NSE/BSE Forecast News and Live Quotes

Equitymaster, 22 Sept

Q3 Results Next Week, 12-16 Jan: TCS, Infosys, Reliance, HCL, HDFC, ICICI Among Key BSE Heavyweights In Focus

Goodreturns, 10 JanResults

🟡Mixed / dependsA results event. The figures on this page update once the new statements reach the data feed, which usually lags the announcement.

Biotechnology Stocks In India -Top Biotechnology Stocks List

Alice Blue, 11 Mar

Sensex crashes 500 points, Nifty 50 ends below 25,600; investors lose over ₹2 lakh crore— 10 key highlights

Livemint, 04 Nov

Genetically Engineered Babies Are Banned. Tech Titans Are Trying to Make One Anyway.

WSJ, 08 Nov

Watch Items

Revenue growth is negative (-57.8%) on the latest reported period — check if this is one-off or a trend.
Cross-check against the company's latest quarterly filing / investor presentation before acting.
1 metric couldn't be retrieved for this stock — this is more common for smaller or thinly-covered listings.
RSI is in overbought territory — momentum entries here carry more short-term pullback risk.

DalalBaazaar Thesis

MiddlingBusiness Quality · Financial Health

WeakGrowth · Profitability · Valuation · Risk

Points for each in the Score ↑

Weak on the fundamentals

Poor scores on business quality without a price low enough to compensate. There is no obvious argument for owning this over a stronger company at a similar valuation. 1 high-severity red flag sits above this conclusion and should be read first.

3 of 4 tripwires tripped — Free cash flow remains positive; ROCE stays above 8%; Valuation vs its own median of 26.2x · see Key things to watch ↑